Bicycle Therapeutics (BCYC) (“the company”) was founded in 2009 and is based in Cambridge, the UK, and Cambridge, Massachusetts.
What are Bicycle peptides:
Bicycle peptides are fully synthetic short peptides constrained to form two loops using a chemical connector compound known as a scaffold, which stabilizes their structural geometry. The company uses a proprietary phage display screening platform for the cyclization of linear peptides and their screening. The science behind bicycle peptides originated in the labs of the company’s co-founder Greg Winter, 2018 Nobel Prize winner British biochemist who is known for his work on